Formerly known as SlipChip Corp, the firm has recently won nearly $10 million in funding to hone its approaches to sepsis and CT/NG testing.
The company has built a small and rugged system boasting 20-minute qPCR reactions and plans to expand the platform for other types of diagnostics.
The non-profit group is interested in improving manufacturing efficiencies to make point-of-care diagnostics more accessible.
Twelve hospitals will use the company's assays to screen vulnerable patients for genes from multi-drug resistant organisms.
Researchers hope to advance the technology to support an assay to help personalize oral cancer treatment by avoiding the development of mucositis.
The partners will leverage IME's rare cell isolation technology, a microchip containing a microfabricated filter membrane to isolate and enrich fetal cells from maternal blood.
The portable analyzer runs an RT-qPCR-based Ebola assay and takes about 75 minutes to detect the presence of the virus from whole blood.
NEW YORK (GenomeWeb News) – Molecular diagnostics company Rheonix today announced a joint development agreement with Life Technologies aimed at a molecular testing platform for the applied markets.
By Tony Fong
A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.
A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.
In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.
A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.